Last reviewed · How we verify
NCT06175429: PREDICT
Prognostic Value of Exhaled Isoprene Levels for Morbidity and Functional Outcome in Cardiosurgical Patients
trial testing Physical performance testing in Frailty in 66 participants. Status unknown.
1 October 2025
Quick facts
| Lead sponsor | University of Rostock |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 66 |
| Start date | 27 November 2023 |
| Primary completion | 1 October 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Physical performance testing
- Breath sampling and VOC analysis
- Muscle ultrasound
- Blood-based biomarker analysis
Conditions studied
- Frailty — all drugs for Frailty →
- Muscle Weakness — all drugs for Muscle Weakness →
- Volatile Organic Compounds — all drugs for Volatile Organic Compounds →
- Isoprene — all drugs for Isoprene →
Sponsor
University of Rostock
Who can join
65 and older, any sex, with Frailty or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The perioperative preservation of functionality and quality of life plays an increasingly important role in older physically limited and frail patients undergoing cardiac surgery. Hereby, impairments of the skeletal muscle system integrity often contributes to a reduced physical performance. Early identification of these high-risk patients could help to initiate appropriate preventive and therapeutic measures. Volatile organic compounds (VOC) represent a non-invasive and real-time measurable approach for recording physiological and pathophysiological processes. Isoprene (2-methyl-1,3-butadiene) is one of the most abundantly exhaled VOCs and has recently been shown to originate from skeletal muscle metabolism. However, the prognostic value of isoprene as a volatile biomarker for skeletal muscle integrity, physical performance and functional outcome in patients undergoing cardiac surgery has not been evaluated before.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06175429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Frailty
Currently open trials in the same condition.
- NCT07481188 — Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery · recruiting
- NCT07519603 — Frailty in Older Adults With Chronic Obstructive Pulmonary Disease (COPD) and Outcomes of the VIVIFRAIL Program · NA · recruiting
- NCT07144527 — Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults · NA · recruiting
- NCT07392944 — Multicomponent Exercise Program on Physical Function, Cognition and Falls Risk Among Older Adults Living in Nursing Home · NA · recruiting
- NCT07475767 — Ultrasound Indicators of Nutritional Status and Treatment Outcomes in Surgical Patients in the Intensive Care Unit · recruiting
Other University of Rostock trials
Trials by the same sponsor.
- NCT06489470 — Strokectomy in Malignant Cerebral Media Infarction · NA · recruiting
- NCT04972617 — Characterization of the Efficacy of Furosemide Depending on Albumin Function · completed
- NCT06318208 — Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19 · completed
- NCT05885620 — SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia · NA · completed
- NCT04541602 — Detection of Neuromuscular Complications in Critically Ill Patients · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06175429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rostock
- Last refreshed: 18 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06175429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing